Actinogen Medical Limited (ASX:ACW)
Australia · Delayed Price · Currency is AUD 0.0450
0.00 (0.00%)
Jan 28, 2026, 4:10 PM AEST
Actinogen Medical Revenue
In the fiscal year ending June 30, 2025, Actinogen Medical had annual revenue of 5.49M AUD, down -44.73%. Actinogen Medical had revenue of 5.49M in the half year ending June 30, 2025, with 41.34% growth.
Revenue
5.49M
Revenue Growth
-44.73%
P/S Ratio
26.16
Revenue / Employee
914.93K
Employees
6
Market Cap
143.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.49M | -4.44M | -44.73% |
| Jun 30, 2024 | 9.93M | 5.04M | 103.18% |
| Jun 30, 2023 | 4.89M | 1.25M | 34.28% |
| Jun 30, 2022 | 3.64M | 1.66M | 83.47% |
| Jun 30, 2021 | 1.98M | -1.53M | -43.58% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthocell | 7.55M |
| Recce Pharmaceuticals | 7.51M |
| Starpharma Holdings | 5.85M |
| Botanix Pharmaceuticals | 5.79M |
| Imugene | 4.40M |
| Arovella Therapeutics | 3.44M |
| Proteomics International Laboratories | 3.31M |
| LTR Pharma | 1.51M |
Actinogen Medical News
- 6 weeks ago - Final, 247th participant randomized and commences treatment in Actinogen's XanaMIA pivotal phase 2b/3 Alzheimer's trial - Benzinga
- 9 months ago - Actinogen provides pivotal Alzheimer's trial enrolment update and other business news - Benzinga